Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0030193 (pain)
 261,466 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

1. When six female seropositive rheumatoid patients were given placebo therapy for 48 h, their plasma kininogen level, 9.2 +/- 0.7 microgram bradykinin equivalents (bk eq) per ml, was found to be 59% greater than that of a group of eight healthy female volunteers (5.8 +/- 0.5 microgram/ml). 2. When the rheumatoid patients received aspirin therapy for 1 week, their mean plasma kininogen concentration fell by 31% to 6.3 +/- 0.8 microgram Bk eq/ml. This was accompanied by a 20.4% fall in mean plasma alpha 2-globulin level. Haematocrit and total plasma protein were not significantly altered (P > 0.05). 3. The fall in kininogen was very rapid, the main reduction occurring within the first hour. 4. Aspirin therapy greatly reduced the pain assessments but had no effect on plasma concentrations of IgG, IgA, IgM, complement component C3, nor on ESR, haemoglobin, leucocyte count, nor ring size. Left hand grip strength was increased while right hand grip strength was unchanged. 5. The action of aspirin on plasma kininogen and alpha 2-globulin was similar to that of indomethacin. Plasma kininogen has been considered to be an acute phase reactant. The possible diagnostic value of plasma kininogen estimation is discussed.
 ...
PMID:The action of aspirin on plasma kininogen and other plasma proteins in rheumatoid patients: relationship to disease activity. 615 90

The cases of a 43 years old-man with gout and a 24 years-old woman with severe back pain who developed dextro-propoxyphene addiction during pain treatment are reported. They had severe edema and fibrosis of skin, subcutaneous tissue and muscle involving the upper and lower limbs. ESR was elevated, CPK and LDH were normal. EMG in proximal muscles showed decreased duration and voltage of potentials, excess of short polyphasics and increased recruitment (BSAP), with positive waves and fibrillations; distal muscles had fasciculations, fibrillations, positive waves, normal voluntary potentials, decreased recruitment. Lymphography indicate delayed progression of contrast media and obstruction in the thighs. Muscle biopsy on fresh-frozen section and histochemistry showed extensive connective tissue proliferation with intense acid and alkaline phosphatase activity in the perimysial and endomysial area, infiltration of lymphocytes near and around small vessels and capillaries. There were perifascicular and type II fiber atrophy. After discharge the patients returned to propoxyphene addiction and the symptoms who subsided during drug withdrawal come back again. New admission, new drug withdrawal and they were discharged free of symptoms and pathologic changes.
 ...
PMID:[Myopathy caused by propoxyphene: report of 2 cases with muscle histochemistry]. 616 47

C-reactive protein (CRP) levels were measured in 105 patients with rheumatoid arthritis (RA) during treatment with slow-acting anti-rheumatoid drugs D-penicillamine, alclofenac, hydroxychloroquine, gold, sulphasalazine and azathioprine. A control group treated with aspirin alone was also included. Patients were assessed clinically (pain score, articular index and summated change score) and in terms of acute-phase reactants (CRP, haptoglobin, fibrinogen, ESR and plasma viscosity) at eight separate clinic visits during the 6-month treatment period. The estimation of CRP was found to be more useful than haptoglobin, fibrinogen or ESR as an index of disease activity.
 ...
PMID:C-reactive protein in the serial assessment of disease activity in rheumatoid arthritis. 620 5

20 patients with active rheumatoid arthritis were treated for 12 weeks with the prostaglandin E1 precursors cis-linoleic acid and gamma-linolenic acid in the form of primrose evening oil (Efamol) and the co-factors zinc, ascorbic acid, niacin, and pyridoxin (Efavit). There was a slight fall in skin reactivity to UV light during the treatment, but no effect on plasma or urine concentrations of PGE1, cAMP or cGMP. There was no effect of the treatment on ESR, P-fibrinogen, number of tender joints, number of swollen joints, the duration of morning stiffness, or on the patient's estimation of pain.
 ...
PMID:Treatment of rheumatoid arthritis with prostaglandin E1 precursors cis-linoleic acid and gamma-linolenic acid. 630 71

Seventy patients between the ages of 18 to 30 with early spondylitis (eAS), with bilateral grade II-III sacroiliitis without syndesmophytes were examined. The control group comprised 32 patients of the same age range with lumbar disc disease (LDD) confirmed by radiculography, without changes in the sacroiliac joints. In both groups the same clinical parameters were evaluated, calculating for each the specificity, sensitivity and Youden index. Statistical analysis was done using Student's t-test and/or the chi-square test. A complex of simple clinical features was isolated suggesting presence of eAS in young subjects with persistent low back pain but without a clear-cut radiological appearance of the sacroiliac joints. The complex included: a history of morning back stiffness, swelling of knee joints, thoracic pain, clinical evidence of limited chest expansion below 5 cm, swelling of joints of lower extremities, positive Mennell's sign, and in laboratory investigations presence of raised ESR and HLA B27-antigen.
 ...
PMID:Clinical symptoms and signs useful in the early diagnosis of ankylosing spondylitis. 633 62

Forty patients affected by various rheumatic disorders (mainly osteoarthritis) were treated with flurbiprofen (300 mg daily) or diclofenac (200 mg daily) in a two-week, parallel group, randomized trial. Both drugs were clinically effective in all the parameters except for fingertip-to-floor distance and ESR. Flurbiprofen proved to be more effective than diclofenac in reducing pain on movement (p less than 0.01) and number of swollen joints (p less than 0.05). The doctor's overall assessment favoured flurbiprofen (p less than 0.10). The incidence and severity of side-effects were low and similar with the two drugs.
 ...
PMID:Controlled study on flurbiprofen and diclofenac in the treatment of rheumatic disorders. 634 28

The physiological cost of gait (PCG) provides a technique for reproducibly quantifying the physical disabilities occasioned by inflammatory joint disease. The preferred walking speed (PWS) and the physiological cost index (PCI) related to achieving that PWS are shown to be abnormal in rheumatoid arthritis (RA) and objective improvement can be demonstrated with naproxen and indomethacin, two commonly-used nonsteroidal anti-inflammatory drugs (NSAIDs). Twenty patients with active RA were studied by double-blind cross-over technique and 16 completed the two-month study. Reliable PCG data obtained in 13 patients showed statistically significant improvement in PWS and PCI with NSAID therapy. Improvement was not correlated with conventional clinical measures of joint inflammation such as pain score, articular index, haemoglobin or ESR but the trends were similar. PCG may offer a reproducible, objective method of quantifying disability and response to treatment.
 ...
PMID:The physiological cost of gait (PCG): a new technique for evaluating nonsteroidal anti-inflammatory drugs in rheumatoid arthritis. 634 5

A six-month single-blind, randomized parallel group study comparing the effects of fenclofenac and diclofenac in 63 patients with rheumatoid arthritis is described. Both treatments produced improvements in clinical measurements, with a significant between-treatment effect in favour of fenclofenac for overall pain, night pain and duration of morning stiffness. Both treatments produced a decrease in IgM and the fenclofenac group produced decreases in plasma viscosity and ESR, the latter showing a significant between-treatment effect in favour of fenclofenac. No clinically significant changes in routine haematology and biochemistry were noted. Unwanted effects leading to withdrawal of therapy were reported by five patients in the fenclofenac group and three patients in the diclofenac group. Two patients in the fenclofenac group and one in the diclofenac group were withdrawn for reasons unrelated to therapy. In the diclofenac group two and four patients were withdrawn for clinical deterioration and inadequate effect respectively.
 ...
PMID:Fenclofenac and diclofenac in the treatment of rheumatoid arthritis. 637 7

The efficacy of a new non-steroidal anti-inflammatory drug (NSAID), GP 53.633 (GP), was tested versus placebo in a double-blind cross-over study. 24 healthy young individuals with impacted asymptomatic lower third molars, of similar shape and position in the jaw on both sides, underwent surgery on 2 separate occasions. The patients randomly received the active drug at one and placebo at the other operation. A number of subjective and objective assessments were made for paired comparison, including: pain, local temperature, swelling, post-operative bleeding, trismus, adverse effects, preference scores, wound healing, bone regeneration and laboratory examinations. The drug caused a significant reduction of post-operative pain, swelling and trismus. Global therapeutic effect and preference scores were highly in favour of the active drug. In the GP period, there was a statistically significant reduction in Hgb, RBC, lymphocytes and ESR, and an increase in neutrophils 3 days after the operation, compared to placebo. Individual values indicate a potentially clinically relevant effect of GP on Hgb and RBC. The clinical relevance of the changes in neutrophil and lymphocyte count, however, is questionable. The drug seemed to have no influence on the other laboratory parameters studied. Adverse effects occurred in 2 patients on GP and in 7 patients on placebo. The drug compares favourably with other NSAID tested in the same model.
 ...
PMID:The rise and fall of a new anti-inflammatory analgesic. 642 31

In 8 European countries a multicentre trial was started in 672 patients with RA. The safety and efficacy of Auranofin (oral gold), was evaluated. There seems to be no difference in response to treatment between patients treated with Auranofin 3 mg twice daily or 6 mg once daily. From the fourth month of treatment there is a statistically difference in improvements for following parameters : activity index of Chalkins, articular index of Lansbury, ESR, pain, morning stiffness, grip strength, number of swollen joints and number of tender joints. These data suggest that Auranofin can be considered as a valuable disease modifying antirheumatic drug (DMARD) in RA and that early onset of therapy can be advised. In most cases the treatment is well tolerated.
 ...
PMID:An European open multicentre trial with auranofin in rheumatoid arthritis. 643 11


<< Previous 1 2 3 4 5 6 7 8 9 10 Next >>